Genmab (NASDAQ:GMAB) reported quarterly earnings results on February 17, 2026 that fell short of analyst expectations. The Healthcare company reported earnings per share of $0.05,…
Genmab (NASDAQ:GMAB) reported quarterly earnings results on February 17, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $0.05, missing the consensus estimate of $0.44 by $0.39 per share. Revenue came in at $1.1B, missing the estimate of $4.4B.
Genmab's stock moved following the earnings release. The stock currently trades at $28.84 with a market capitalization of $19.9B.
Our Markets Team monitors market data, SEC filings, analyst actions, earnings releases, and corporate announcements to produce timely updates for investors.
Current market data
NASDAQ · GMAB
$34.10
Down: -$0.67 · -1.96%
Live quote updated
Keep reading
